Evidence map›Paper›PMID 30067306›Full record

Trial reportLiver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society2019

Plasma From Patients Undergoing Liver Transplantation Is Resistant to Anticoagulant Activity of Soluble Thrombomodulin.

Laura C Burlage, Sarah Bos, Jelle Adelmeijer, Takumi Sakai, Robert J Porte, Ton Lisman

Abstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Laura C BurlageSection of HPB Surgery and Liver Transplantation.
Sarah BosSurgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Jelle AdelmeijerSurgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Takumi SakaiDevelopment Planning, Clinical Department Center, Asahi Kasei Pharma Corporation, Tokyo, Japan.
Robert J PorteSection of HPB Surgery and Liver Transplantation.
Ton LismanSection of HPB Surgery and Liver Transplantation.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Recombinant human soluble thrombomodulin (ART-123) is an anticoagulant and anti-inflammatory agent clinically used for treatment of disseminated intravascular coagulation. Preclinical studies have shown that ART-123 reduces hepatic ischemia/reperfusion. Although ART-123 may therefore have clinical benefit in orthotopic liver transplantation, the substantial alterations in the hemostatic system may complicate its use in this setting. Here, we studied the in vitro effect of ART-123 on coagulation of patients with end-stage liver disease undergoing liver transplantation. Ten patients with end-stage liver disease undergoing liver transplantation were included in this study. Plasma samples of 10 healthy individuals were included to establish reference values. Different concentrations of ART-123 were added to plasma samples, and peak thrombin generation and clot lysis times (CLTs) were determined. In patient samples, plasma was profoundly resistant to the anticoagulant action of ART-123, as reflected by significantly higher median inhibitory concentration (IC

Indexed as

AnticoagulantsBlood CoagulationDose-Response Relationship, DrugEnd Stage Liver DiseaseFactor VIIIFemaleFibrin Clot Lysis TimeFibrinolysisHealthy VolunteersHemorrhageHumansInhibitory Concentration 50Liver TransplantationMaleMiddle AgedRecombinant ProteinsAnticoagulantsART123F8 protein, humanFactor VIIIRecombinant ProteinsThrombinThrombomodulin

Identifiers

PMID30067306
PMCPMC6590179

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.